Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis

AIDS

Volumn 18, Issue 3, 2004, Pages 567-569

  Sklar, Peter A ^a   Agyemang, Amma F ^b   Monastra, Rachelle ^b   Kress, Diane Rock ^b   Metcalf, Julia A ^b   Robinson, Michael R ^c   Masur, Henry ^a   Polis, Michael A ^b  

^a CLINICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROTEINASE INHIBITOR;

ARTICLE; CELL COUNT; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DISEASE COURSE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RELAPSE; RETINITIS; SURVIVAL; T LYMPHOCYTE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE;

EID: 1642339454     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00027     Document Type: Article

References (13)

1. Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633-1637.
2. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001; 15:23-31.
3. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126:817-822.
4. Tural C, Romeu J, Sirera C, Audreu D, Conejero M, Ruiz S, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177:1080-1083.
5. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177: 1182-1187.
6. Berenguer J, Gonzalez J, Pulido F, Padilla B, Casado JL, Rubio R, et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretrovirviral therapy. Clin Infect Dis 2002; 34:394-397.
7. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-367.
8. Palestine AG, Rodrigues MM, Macher AM, Chan CC, Lane HC, Fauci AS, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91:1092-1099.
9. Henderly DE, Freeman WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94:425-434.
10. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 67:473-486.
11. Holland GN, Sison RF, Jatulis DE, Haslop MG, Sakamoto MJ, Wheeler NC. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group. Ophthalmology 1990; 97:204-211.
12. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquired Immune Defic Syndr 2001; 27:168-175.
13. Le Moing V, Thiebaut R, Chene G, Leport C, Cailleton V, Michelet C, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471-480.